The Characterization of the Novel Chloroquine Derivative VR23 for its Anticancer Properties
Since Bortezomib®, a proteasome inhibitor, was approved by US FDA for the treatment of multiple myeloma in 2003, proteasome is recognized as one of the most promising targets for cancer therapeutics. The proteasomes play a critical role in regulating the level of cellular proteins and recycling dama...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en |
| Published: |
Université d'Ottawa / University of Ottawa
2015
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10393/32405 http://dx.doi.org/10.20381/ruor-4368 |